The Pathogenesis and Therapeutics of Nasopharyngeal Carcinoma

The hypermethylation of RASSF1A might decrease overall survival (OS) rate in EBVpositive NPC, and induce the pathogenesis of EBV-infected NPC [34]. Besides the existence of EBV in majority of NPC cases, particularly type II and III, in the endemic areas, human papillomavirus (HPV) was also observed...

Full description

Saved in:
Bibliographic Details
Published in:Health science journal 2019-01, Vol.13 (2), p.1-7
Main Authors: He, Ji-Qun, Sun, Lichun, He, Jun, Zhu, Chenhong, Li, Ping, Lei, Jun, He, Quanyong, Mackey, Vienna, Lin, Zhen, Cheng, Pengfei, Coy, David H
Format: Article
Language:English
Subjects:
Epidemiology
Head & neck cancer
Nose
Pathogenesis
Risk factors
Throat
Throat cancer
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The hypermethylation of RASSF1A might decrease overall survival (OS) rate in EBVpositive NPC, and induce the pathogenesis of EBV-infected NPC [34]. Besides the existence of EBV in majority of NPC cases, particularly type II and III, in the endemic areas, human papillomavirus (HPV) was also observed to be involved in NPC, particularly EBV-absent type I NPC. [...]patients are at late stage of NPC once they have been diagnosed. Besides surgery, patients are usually treated with radiotherapy and chemotherapy due to NPC is highly radio-sensitive and chemo-sensitive [8]. The expression of CDX2 and NOX4 was detected in recurrent NPC tumor tissues, but not in other NPC tumor tissues. [...]targeting these proteins or blocking the associated signaling networks may be a potential and novel therapeutics for the treatments of patients with NPC recurrence [41]. [...]the high expression of fibronectin 1 suppressed cell apoptosis in NPC via increasing the expression of BCL2 and the nuclear localization of P65. [...]Fibronectin 1 may be a potential target for new anti-NPC drug development [42].
ISSN:1791-809X
1791-809X
DOI:10.21767/1791-809X.1000642